Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant trastuzumab duration trial in HER2-positive early breast cancer
ACTRN12607000011482Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2002
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab in breast cancer (3 arms), sponsored by Roche. Primary endpoints: Disease-free survival for 1 year trastuzumab versus no trastuzumab and Disease-free survival for 2 years trastuzumab versus no trastuzumab. Started Jul 2002; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12607000011482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000011482.